's () Neil Clarke talks to Proactive London's Katie Pilbeam about the XF-73 Phase 2b clinical trial which is now fully recruited.
The plan is to finalise the phase 2 data in the first quarter then move on to phase 3, with discussions already taking place as to how this is going to work, in regards to the amount of patients that will be taking part.
Destiny is focused on medicines that can prevent life-threatening infections after operations in hospitals. XF-73 is designed to prevent post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Destiny Pharma PLC named herein, including the promotion by the Company of Destiny Pharma PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE